All In Biotech

Drug Trial Radar · NCT06216158

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

A Randomized Phase III Trial Assessing Iberdomide Versus Iberdomide Plus Isatuximab Maintenance Therapy Post Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 411 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

411

Planned (sponsor's estimate)

Start

Apr 5, 2024

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Lead sponsor
University of Heidelberg Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
KKS Netzwerk; Wuerzburg University Hospital; Sanofi; Bristol-Myers Squibb
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen. The trial is the subsequent maintenance therapy to GMMG-HD8/DSMM XIX trial for patients with newly-diagnosed multiple myeloma. Patients with newly-diagnosed multiple myeloma who underwent a similar quadruplet induction/consolidation therapy regimen followed by at least one ASCT can also be recruited. The main question it aims to answer is: • Will the addition of isatuximab lead to decreased amounts of measurable myeloma cells in the bone marrow after two years?

Conditions

  • Multiple Myeloma

Interventions

  • IberdomideDrug

    Iberdomide p.o. (0.75 mg, day 1-21 of each 29-days cycle)

  • IsatuximabDrug

    Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)

  • DexamethasoneDrug

    Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstration of superiority of iberdomide plus isatuximab compared to iberdomide with respect to bone marrow minimal residual disease (MRD).Time frame: 24 months after start of maintenance therapy

Locations

69 sites in 2 countries. Site status is shown where the registry gives one.

  • Universitätsklinikum Krems an der Donau

    Krems, Austria

  • Ordensklinikum Linz Elisabethinen

    Linz, Austria

  • Landeskrankenhaus Salzburg, Universitätsklinik für Innere Medizin III

    Salzburg, Austria

  • Klinik Ottakring Wien

    Vienna, Austria

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Austria

  • Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation

    Aachen, Germany

  • Universitätsklinikum

    Augsburg, Germany

  • Helios Klinikum Bad Saarow

    Bad Saarow, Germany

  • Charité, III. Medizinische Abteilung

    Berlin, Germany

  • Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie

    Berlin, Germany

  • Helios Klinikum Berlin-Buch

    Berlin, Germany

  • Onkologische Schwerpunktpraxis Bielefeld

    Bielefeld, Germany

  • Evangelisches Klinikum Bethel

    Bielefeld, Germany

  • Johanniter Krankenhaus

    Bonn, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Städtisches Klinikum

    Braunschweig, Germany

  • Klinikum Chemnitz

    Chemnitz, Germany

  • Carl-Thiem-Klinikum Cottbus gGmbH, 2. Medizinische Klinik

    Cottbus, Germany

  • Klinikum Darmstadt GmbH, Medizinische Klinik V

    Darmstadt, Germany

  • Städtisches Klinikum

    Dessau, Germany

  • St. Johannes Hospital Dortmund

    Dortmund, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Marien Hospital Düsseldorf GmbH, Klinik für Onkologie, Hämatalogie und Palliativmedizin

    Düsseldorf, Germany

  • St. Antonius-Hospital

    Eschweiler, Germany

  • KEM I Evang. Kliniken Essen-Mitte gGmbH, Evangelisches Krankenhaus Essen-Werden gGmbH, Klinik für Hämatologie, Onkologie und Stammzelltransplantation

    Essen, Germany

  • Malteser Krankenhaus

    Flensburg, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Centrum für Hämatologie und Onkologie Bethanien

    Frankfurt am Main, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Universitätsmedizin Greifswald

    Greifswald, Germany

  • Katholisches Krankenhaus Hagen

    Hagen, Germany

  • Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie

    Hamburg, Germany

  • Asklepios Klinik Altona

    Hamburg, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Onkologische Schwerpunktpraxis

    Heidelberg, Germany

  • Universitätsklinikum Heidelberg, Medizinische Klinik V

    Heidelberg, Germany

  • SLK Kliniken Heilbronn, Medizinische Klinik III

    Heilbronn, Germany

  • Universitätsklinikum des Saarlandes, Klinik für Innere Medizin 1

    Homburg, Germany

  • Klinikum der Friedrich-Schiller-Universität Jena, Klinik für Innere Medizin II, Abteilung Hämatologie und internistische Onkologie

    Jena, Germany

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.